Sanofi Consumer Healthcare India Valuation

Is SANOFICONR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SANOFICONR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SANOFICONR (₹4781.95) is trading above our estimate of fair value (₹2131.94)

Significantly Below Fair Value: SANOFICONR is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SANOFICONR?

Key metric: As SANOFICONR is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SANOFICONR. This is calculated by dividing SANOFICONR's market cap by their current revenue.
What is SANOFICONR's PS Ratio?
PS Ratio	47.6x
Sales	₹2.31b
Market Cap	₹110.13b

SANOFICONR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	47.2x
Enterprise Value/EBITDA	n/a
PEG Ratio	6.6x

Price to Sales Ratio vs Peers

How does SANOFICONR's PS Ratio compare to its peers?

The above table shows the PS ratio for SANOFICONR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.6x
AETHER Aether Industries	16.7x	35.2%	₹108.8b
GLS Glenmark Life Sciences	6x	15.0%	₹132.7b
BLUEJET Blue Jet Healthcare	12.6x	25.9%	₹90.7b
532482 Granules India	3.2x	13.7%	₹141.3b
SANOFICONR Sanofi Consumer Healthcare India	47.6x	35.7%	₹110.1b

Price-To-Sales vs Peers: SANOFICONR is expensive based on its Price-To-Sales Ratio (47.6x) compared to the peer average (9.6x).

Price to Sales Ratio vs Industry

How does SANOFICONR's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.4x	n/a	US$87.67m
539561 Remedium Lifecare	0.07x	n/a	US$26.84m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$20.05m
524412 Aarey Drugs & Pharmaceuticals	0.3x	n/a	US$19.21m

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SANOFICONR is expensive based on its Price-To-Sales Ratio (47.6x) compared to the Indian Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is SANOFICONR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SANOFICONR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	47.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SANOFICONR's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

0.8%

-23.0%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,058.30

3.5%

52.4%